Pictet Asset Management (Switzerland)’s Nektar Therapeutics NKTR Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-248,045	Closed	-$2.62M	–	2000
2023 Q1	$2.62M	Buy	248,045 +170,987	+222%	+$5.17M	﹤0.01%	892
2022 Q4	$2.61M	Buy	77,058 +19,710	+34%	+$954K	﹤0.01%	882
2022 Q3	$2.75M	Buy	57,348 +34,398	+150%	+$2.05M	﹤0.01%	858
2022 Q2	$1.31M	Buy	22,950 +22,032	+2,400%	+$1.39M	﹤0.01%	1008
2022 Q1	$74K	Hold	918	–	–	﹤0.01%	1633
2021 Q4	$186K	Hold	918	–	–	﹤0.01%	1614
2021 Q3	$247K	Buy	+918	New	+$221K	﹤0.01%	1506

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s NKTR Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 248,045 shares — an estimated $2.62M sold.

Pictet Asset Management (Switzerland) first reported a position in NKTR in Q3 2021 and held it in 7 quarters. The position peaked at $2.75M in Q3 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Pictet Asset Management (Switzerland) reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 248,045 Nektar Therapeutics shares in Q2 2023, an estimated $2.62M.
Pictet Asset Management (Switzerland) first reported a position in Nektar Therapeutics in Q3 2021 and held it in 7 quarters.
Pictet Asset Management (Switzerland)'s Nektar Therapeutics position peaked at $2.75M in Q3 2022.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.